Golden
Relmada Therapeutics

Relmada Therapeutics

A company that deveops therapeutics for depression, CNS and ophthalmological disorders

Relmada Therapeutics is a publicly owned, clinical-stage pharmaceutical company based in New York City, New York that was founded in 2004 by Najib Babul. It focuses on developing new modified versions of proven drug products together with new chemical entities that could address the treatment of central nervous system (CNS) diseases, opthalmological disorders, major depressive disorder, and chronic pain. 

Products

The company has four products in its pipeline, at various stages of development. They include:

  • REL-1017
  • REL-1021
  • REL-1028
  • REL-1015

REL-1017

REL-1017 is d-methadone (dextromethadone), a type of N-methyl-D-aspartate (NMDA) receptor antagonist. It is being developed as a possible treatment for MDD, Rett Syndrome, Opthalmological disorders, and mitochondrial diseases & ALS. Relmada began Phase 2 clinical studies of the product for MDD in June 2017. This phase of the study is expected to be completed with top line results available for release in the first half of 2019. As for the treatment of the other illnesses, REL-1017 is still in the pre-clinical stages.

REL-1015

REL-1015, also known as LevoCap ER, is an extended release, abuse deterrent formulation of the opiod analgesic, levorphanol. It is a type of strong opiod that is differentiated from morphine, oxycodone, and others for the management of chronic pain. In clinical studies, levorphanol has demonstrated a broad spectrum of analgesic activity against different types of pain inclluding neuropathic pain, post-surgical pain, and chronic pain. REL-1015 has completed Phase 1 studies and as of December 2018 has no studies ongoing. However, Under the 505(b)2 regulatory pathway, LevoCap could go directly into Phase 3 studies.

REL-1028

REL-1028 (BuTab) is a new oral formulation of the modified release buprenorphine, which is being developed for both chronic pain and opiod dependence indications. Relmada has completed a pre-clinical program to define the pharmacokinetic profile of REL-1028.

REL-1021

REL-1021, also known as MepiGel) is a topical dosage form of local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as diabetic neuropathy, postherpetic neuralgia, and HIV-associated neuropathy. The product is currently indicated for infiltration, nerve block, and epidural anesthesia. Relmada has received two FDA Orphan Drug Designations for mepivacaine, one each for the treatment of painful HIV-associated neuropathy and for the management of postherpetic neuralgia. The formulations to be advanced into clinical studies for MepiGel have been selected after evaluations from in vitro and ex vivo studies comparing various topical prototypes. It has also completed toxicology studies. 

Funding

Series A

On October 1, 2013 Relmada Therapeutics completed their series A funding round with $8 million in funding from undisclosed investors. 

Venture round

On May 22, 2014 Relmada Therapeutics completed a venture capital round with $15.1 million in funding from BioAdvance. 

Convertible notes

On October 5, 2017 Relmada Therpeutics announced a private placement of convertible promissory notes to new and existing investors which provided the company with approximately $6.9 million in gross proceeds. 

Timeline

October 5, 2017

Convertible notes

On October 5, 2017 Relmada Therpeutics announced a private placement of convertible promissory notes to new and existing investors which provided the company with approximately $6.9 million in gross proceeds. 

May 22, 2014

Venture funding round

On May 22, 2014 Relmada Therapeutics completed a venture capital round with $15.1 million in funding from BioAdvance. 

October 1, 2013

Series A funding round

On October 1, 2013 Relmada Therapeutics completed their series A funding round with $8 million in funding from undisclosed investors. 

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Dr. Ottavio Vitolo

Senior VP, Head of R&D, and Chief Medical Officer



Marie Chang

Employee



Nico Riggio

Investor



Raja Appachi

Investor



Sergio Traversa

CEO & Interim CFO



Further reading

Title
Author
Link
Type
Date

Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder

Relmada Therapeutics

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References